Kornimate/medical-research-clean huggingface dataset:
trunk control, balance, gait, functional mobility and fear of falling in people with alzheimer's disease

Conditions: Physical Therapy

Summary: the purposes of this study were to investigate the relationship between trunk control and balance, gait, functional mobility, and fear of falling in people with alzheimer's disease and to compare trunk control, balance, gait, functional mobility, and fear of falling in people with alzheimer's disease and healthy older adults. balance, an essential motor skill necessary to perform both static and dynamic everyday activities with stability and security, is impaired in people with alzheimer's disease when compared to cognitively preserved elderlies. gait and functional mobility disorders are also observed in people with alzheimer's disease from the early period of the disease. people with alzheimer's disease tend to fall more often and are more seriously injured from falls than cognitively intact older adults. the annual incidence rate for falling is 60% to 80% for older adults with alzheimer's disease, over twice the incidence of age-matched cognitively intact older adults. trunk control is shown among the most important factors that ensure the balance and walking of the individual in different environments and conditions during functional activities. optimal trunk control relies on adequate somatosensory, motor, and musculoskeletal systems, which are frequently compromised in people with alzheimer's disease. for this reason, the investigators think that trunk control may be affected in people with alzheimer's disease compared to healthy older adults and may be related to balance, gait, functional mobility and fear of falling.

the study was carried out with the purpose of investigating the relationship between trunk control and balance, gait, functional mobility, and fear of falling in people with alzheimer's disease and comparing trunk control, balance, gait, functional mobility, and fear of falling in people with alzheimer's disease and healthy older adults. 35 people with alzheimer's disease and 33 healthy older adults with matching ages and genders were included the study. trunk control with trunk impairment scale; balance with berg balance scale, functional reach test, one-leg standing test and five-repeat sit-and-stand test; gait with dynamic gait index; functional mobility with timed up and go test; fear of falling with falls efficacy scale-international were evaluated.

Eligibility criteria:
inclusion criteria * clinical diagnosis of alzheimer's disease according to the nincds/ardra diagnostic criteria by a neurologist. * having a cognitive level between 18-23 points according to the mini mental status examination. * must be able to walk independently with and/or without assistive device. exclusion criteria * having a history of cerebrovascular disease, epilepsy and brain tumor. * having a cognitive level below 18 points according to the mini mental status examination.

Keywords: trunk control balance gait functional mobility fear of falling
phase ii study of afatinib plus bevacizumab in the treatment epidermal growth factor receptor (egfr) exon g719x, s768i, and l861q mutation metastatic non-small cell lung cancer

Conditions: PFS

Summary: there is no report afatinib plus bevacizumab in the treatment of egfr g719x, s768i, and l861q single or compond mutation of metastatic non-small-cell lung cancer (nsclc). the purpose of this study is to study afatinib combined with bevacizumab in the management of it.

lung cancer is one of the most common types of cancer and is the most common cause of death from cancer (almost 20 percent \[%\] of cancer deaths); nsclc accounts for 80% to 85% of lung cancers. the hypothesis is that afatinib plus bevacizumab in patients with metastatic nsclc characterized by egfruncommon mutations with g719x, s768i, and l861q. efficacy assessments will include disease assessment, symptomatic progression and patient-reported outcome. safety assessments will include physical examinations, vital signs, electrocardiograms (ecgs), eastern cooperative oncology group (ecog) performance status and clinical safety laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis).

Eligibility criteria:
inclusion criteria: * participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (nsclc) with documented primary epidermal growth factor receptor (egfr) exon g719x, s768i, l861q mutation participant must have measurable disease according to response evaluation criteria in solid tumors (recist) v1.1. participant must have eastern cooperative oncology group (ecog) performance status 0 or 1, or 2 participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream a female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study exclusion criteria: participant has history of spinal cord compression that has not been treated definitively with surgery or radiation participant has a medical history of interstitial lung disease (ild), including drug-induced ild, or radiation pneumonitis participant has a contraindication to the use afatinib or bevacizumab
predicting favorable outcomes in hospitalized covid-19 patients

Conditions: COVID; Corona Virus Infection; Adverse Event

Summary: testing use of predictive analytics to predict which covid-19+ patients are at low risk for an adverse event (icu transfer, intubation, mortality, hospice discharge, re-presentation to the ed, oxygen requirements exceeding nasal cannula at 6l/min) in the next 96 hours

to assess if display of low risk of adverse event in epic can safely reduce length of stay and plan for discharge.

Eligibility criteria:
inclusion criteria: adult hospitalized covid19+ patients predicted to have no adverse event at 96 events with a threshold at 90% ppv, with at least one low risk during their admission who are discharged alive and have not been in the icu exclusion criteria: age \< 18 years not hospitalized for covid19+.
studies of pandemic influenza (h1n1) 2009 vaccine in bergen

Conditions: Healthy

Summary: haukeland university hospital has approximately 8000 employees many of whom will be in the front line to receive the pandemic a/h1n1 vaccine. we propose to conduct a safety and immunogenicity study in these subjects

the investigators will conduct a safety and immunogenicity study in health employees as detailed below: * examine adverse events of all employees after vaccination using adverse events form * examine the immunogenicity of the vaccine by collecting blood samples at days 0, 21 \& 42 after vaccination (up to 500 people) * provide a detailed time course of the immune response to vaccination with a novel influenza h1n1 virus including the kinetics of the t-cell, b-cell and antibody responses in 50 volunteers * investigate the long lasting immunity induced by the vaccine * examine the ability of the vaccine to induce cross-reactive immunity to h1n1 strains.

Eligibility criteria:
inclusion criteria: signed informed consent subjects able to understand and comply with the study protocol and complete the adverse event form subjects able to attend the scheduled visits for the kinetic study exclusion criteria: * persons with a history of anaphylaxis or serious reactions to any vaccine * person with known hypersensitivity to any of the vaccine components * persons who have had a temperature \>38oc during the previous 72 hours * persons who have had an acute respiratory infection during the last 7 days * suspected non-compliance

Keywords: h1n1 pandemic vaccine immunogenicity safety health employees
non-invasive portal and hepatic vein pressure estimation

Conditions: Portal Hypertension

Summary: background portal hypertension (ph) is a spectrum of complications of end-stage liver disease (esld) and cirrhosis, with severe manifestations including ascites and gastroesophageal varices. it is therefore important that timely and easily diagnosing ph has relevant prognostic and therapeutic implications. the current gold standard to evaluate ph is by hepatic vein catheterization using the transjugular approach, and measuring the hepatic venous pressure gradients (hvpg). time-resolved, three-dimensional, three-directional velocity-encoded mri, also termed four-dimensional (4d) flow mri, has been shown superior accuracy over conventional two-dimensional (2d) phase-contrast mri, in particular for quantification of regurgitant volumes and severity of cardiac shunts. recently, the investigators developed new imaging methods based on 4d flow mri for visualization of the vasculature of the abdominal blood flow circulation including the portal vein. using the newly developed computation fluid dynamics (cfd) model the investigators could determine the absolute local blood pressure in the portal vein. preliminary data in healthy volunteers seem promising, however, data in patients with esld including the correlation with invasively measured hvpg are lacking. objectives the primary objective is to develop and validate noninvasive cfd and 4d flow mri based hvpg calculation to estimate portal pressure in patients with end-stage liver disease (esld). methods in 50 adult patients with esld, submitted for liver transplantation (lt) screening, hvpg measurements using the transjugular approach according to the standard lt screening protocol, will be extended by 4d flow mri measurements. anticipated results in patients with esld, portal pressure can be measured by 4d flow mri and will replace the invasive transjugular approach. the measurements can be directly incorporated in the lt screening. moreover, the possibility to easily measure portal pressure will be relevant for all patients with esld at risk for ph. nature and extent of the burden and risks associated with participation, benefit and group relatedness: patients will undergo a single non-invasive mri-examination of one hour long after a four hour period of fasting. the risks associated with non-invasive mri examinations is neglectable.


Eligibility criteria:
inclusion criteria: * eligible for liver transplantation (lt) screening (which excludes pregnancy). * age ≥ 18 years and ≤ 75 (since \>75 is a contraindication for lt). * written informed consent. exclusion criteria: * exclusion criteria for mri (claustrophobia, pacemaker, metal implants, etc.). * a psychiatric, addictive or any other disorder that compromises the subjects ability to understand the study content and to give written informed consent for participation in the study.

Keywords: magnetic resonance imaging computational fluid dynamics noninvasive meal challenge
a 28-day study of diclazuril in the treatment of cryptosporidiosis in patients with aids

Conditions: Cryptosporidiosis; HIV Infections

Summary: to evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in aids patients who have been treated in the double-blind study # jrd 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine (azt). * didanosine (ddi) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more. * aerosolized pentamidine. * nystatin for control of oropharyngeal infections. nystatin must not be taken within two hours of diclazuril. * ganciclovir therapy only for cmv retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug. * loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol. patients must have the following: written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained. * be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up). prior medication: allowed: * diclazuril. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * uncontrolled vomiting. * estimated survival less than 28 days. * other treatable enteric pathogens must be treated and eradicated prior to study entry. concurrent medication: excluded: * amphotericin b. * other antibiotics or antiprotozoal drugs. * other investigational agents. * trimethoprim/sulfamethoxazole. * antifungal medications except nystatin. * ganciclovir for other than cytomegalovirus (cmv) retinitis. * antidiarrheal agents other than patients on long term loperamide prior to study entry. patients with the following are excluded: * undependable in following the instructions of the investigator. * not able to swallow capsules. * uncontrolled vomiting. * estimated survival less than 28 days. prior medication: excluded: * diclazuril within 2 weeks of study entry.

Keywords: aids-related opportunistic infections cryptosporidiosis diarrhea diclazuril coccidiostats acquired immunodeficiency syndrome
magnetic resonance imaging for detection of peritoneal mesothelioma

Conditions: Mesothelioma; Peritoneal Mesothelioma

Summary: for cancers, such as mesothelioma, that spread to the lining of the stomach, detecting the cancer is very difficult with ct or mri scans. researchers at the university of chicago want to find out if the new experimental mri and ultrasound imaging techniques do a better job of detecting these cancers. researchers will use new mri and ultrasound techniques to see if it can find evidence of cancer that has spread to the lining of the abdomen, and right now these new techniques are only used for research.


Eligibility criteria:
inclusion criteria: 1. 18 years old or older 2. biopsy-proven mpm 3. surgery for pm planned at ucm within 60 days 4. able to tolerate ct, mri, us scans, and surgery 5. able to provide written informed consent 6. for women of child bearing age, ability and willingness to use appropriate contraceptive methods before imaging and for a period of 365 days thereafter. exclusion criteria: 1. pregnancy / breastfeeding 2. allergy or intolerance to iodinated or gadolinum contrast dyes 3. contraindications to ct or mri imaging including chronic kidney disease with gfr \<60ml/min/1.73m2 4. bioimplants unsuitable for mri imaging (activated by mechanical, electronic, radiofrequency, or magnetic means), such as cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps 5. permanent tattoos or eyeliner with magnetic dyes 6. subjects with shrapnel or metal fragments lodged in the body 7. anxiety, claustrophobia, or any medical condition that would preclude lying still in an mri scanner for 1-1.5 hours 8. cardiac, circulatory, or perspiration problems leading to impaired thermoregulation 9. respiratory or cardiac impairment limiting the ability to lie flat 10. inability to breath-hold for mri acquisition 11. vascular or aneurysm clips or any other surgical implant that is not mri-compatible 12. any other ferromagnetic bioimplant that would be damaged by mri 13. mental, cognitive, or mental health impairments that preclude the subject from providing informed consent or adhering to the treatment protocol 14. subjects unable to adhere to the protocol or communicate effectively with researchers 15. imprisoned subjects 16. subjects with history of prior crs/hipec or other peritonectomy surgery that might alter characteristics of the peritoneum
compliance and cumulative interceptive rate after therapy of peri-implantitis

Conditions: Peri-Implantitis

Summary: peri-implantitis is a plaque-mediated inflammatory condition featured by progressive bone loss. this entity jeopardizes the longevity of dental implants, thus impacting negatively on the quality of life of patients. moreover, peri-implantitis is suggested to lead to an increased systemic status of inflammation. this may rise the susceptibility to experience life-threating conditions. therefore, peri-implant infections must be promptly diagnosed and eliminated. aiming at resolving the inflammation, several options are advised to remove the infection. accordingly, implant removal or therapeutic manoeuvres to stablish a healthy ecosystem in the peri-implant environment have been suggested. while the former proved being more predictable, the later demonstrated being more conservative. indeed, implant removal is commonly associated with regenerative procedures of the alveolar bone deformity that often demand time and is more costly. anyways, disease severity, implant expendability for biomechanical reasons or esthetic demand seem to be few of the leading aspects in the decision-making process on maintaining or extracting implant showing peri-implant lesions. supportive maintenance care (spt) was shown to be key in preventing disease recurrence. nonetheless, the compliance of these patients is often erratic. in fact, it is yet unknown the rate of compliance after therapy. therefore, the goal of this study is to assess the rate and confounders for compliance.


Eligibility criteria:
inclusion criteria: * patients that underwent treatment of peri-implantitis * \>12 months of follow-up after therapy * patients managed in our center exclusion criteria: * patients that were managed in other centers * patients that have incomplete records
control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or adapalen (differin gel)

Conditions: Acne Papulopustulosa

Summary: the aim of the study is to investigate the effectivity of visible light in combination with waterfiltered infrared in treating acne papulopustulosa. the reduction of inflammatory and non-inflammatory lesions within 8 weeks will be measured and compared with the standard treatment with adapalene.


Eligibility criteria:
inclusion criteria: * mild to moderate acne papulopustulosa according to burton scale stage 3 to 4 * at least 5 inflammatory and 5 non-inflammatory lesions in the face * age \>= 14 years exclusion criteria: * pregnant and nursing women * antiandrogen therapy * therapy with antibiotics within the last 4 weeks * therapy with retinoids within the last 6 months * natural or artificial uv-therapy within the last 4 weeks * severe acne papulopustulosa according to burton scale 5 or 6 * severe systemic condition * secondary acne
verbal stimulation of orientation on emergence agitation

Conditions: Emergence Delirium

Summary: the purpose of this study is to investigate whether information of the orientation such as time, place, and patient's own name can reduce emergence delirium after general anesthesia.


Eligibility criteria:
inclusion criteria: * patients undergoing elective laparoscopic or robot-assisted abdominal surgery exclusion criteria: * patients' refusal * change in operation schedule * american society of anaesthesiologists (asa) physical status ⅳ * day surgery * bmi ≥35 * neurocognitive impairment, hearing disorder * psychological drug intake * experience of general anesthesia or sedation within 1 month drop out criteria * changes in operation schedule (e.g. unexpected collaborative surgery, conversion to laparotomy, delay of the schedule to night-duty hours) * significant protocol violation

Keywords: emergence delirium, emergence agitation, orientation
the aid study: artificial intelligence for colorectal adenoma detection

Conditions: Colon Cancer

Summary: colonoscopy is clinically used as the gold standard for detection of colon cancer (crc) and removal of adenomatous polyps. despite the success of colonoscopy in reducing cancer-related deaths, there exists a disappointing level of adenomas missed at colonoscopy. "back-to-back" colonoscopies have indicated significant miss rates of 27% for small adenomas (\< 5 mm) and 6% for adenomas of more than 10 mm in diameter. studies performing both ct colonography and colonoscopy estimate that the colonoscopy miss rate for polyps over 10 mm in size may be as high as 12%. the clinical importance of missed lesions should be emphasized because these lesions may ultimately progress to crc8. limitations in human visual perception and other human biases such as fatigue, distraction, level of alertness during examination increases such recognition errors and way of mitigating them may be the key to improve polyp detection and further reduction in mortality from crc. in the past years, a number of cad systems for detection of polyps from endoscopy images have been described. however, the benefits of traditional cad technologies in colonoscopy appear to be contradictory, therefore they should be improved to be ultimately considered useful. recent advances in artificial intelligence (ai), deep learning (dl), and computer vision have shown potential to assist polyp detection during colonoscopy.


Eligibility criteria:
inclusion criteria: all 40-80 years-old subjects undergoing a colonoscopy. exclusion criteria: * subjects with personal history of crc, or ibd. * patients with inadequate bowel preparation (defined as boston bowel preparation scale \> 2 in any colonic segment). * patients with previous colonic resection. * patients on antithrombotic therapy, precluding polyp resection. * patients who were not able or refused to give informed written consent.

Keywords: artificial intelligence
to evaluate the therapeutic equivalence and safety of tretinoin cream, 0.05% and rld in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: bioequivalence study comparing tretinoin cream, 0.05% to retin-a®.

a multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing tretinoin cream, 0.05% (taro pharmaceuticals u.s.a., inc.) to retin-a® (tretinoin) cream, 0.05% (valeant) and both active treatments to a placebo control in the treatment of acne vulgaris

Eligibility criteria:
inclusion criteria: * healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris. * subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the investigator's global assessment (iga) (per table 1 below). exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation * subjects with a history of hypersensitivity or allergy to tretinoin, retinoids, or any of the study medication ingredients.
laser ablation of abnormal neurological tissue using robotic neuroblate system

Conditions: Metastatic Brain Tumor; Primary Brain Tumor; Epileptic/Seizure Foci; Movement Disorders

Summary: the neuroblate® system (nbs) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by monteris medical. since it received fda clearance in may 2009, the nbs has been used in over 2600 procedures conducted at over 70 leading institutions across united states. this is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, qol, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 3,000 patients and up to 50 sites.


Eligibility criteria:
inclusion criteria: 1. subject or legally authorized representative provides written authorization and/or consent 2. subject who is to undergo thermal therapy by the neuroblate® system for treatment of their neurological disorder exclusion criteria: 1. subject who is, or is expected to be inaccessible for follow-up 2. other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator, may prevent participation or otherwise render subject ineligibility for the study

Keywords: procedural success progression quality of life seizure freedom progression free survival overall survival